SecBot SecBot
8-K ·Filed Nov 5, 2026

SRPT

Sarepta Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed11d 8h ago SEC0001193125-26-449822
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The Q4 2026 MAD data readouts for SRP-1003 (DM1) and SRP-1001 (FSHD) are the next major catalysts; positive results could support Phase 3 advancement and re-rate the stock. The raised revenue guidance and narrowed expense range signal improved operational visibility, but ELEVIDYS revenue remains pressured by the ambulatory-only label.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

SRPT drug pipeline →

AMONDYS 45

◆ Mixed Named in this 8-K
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already on the market under accelerated approval (since February 2021). The sNDA for traditional approval has a PDUFA goal date around April 2027.
Next catalyst
None dated

What to watchWatch for the FDA's decision on the sNDA for traditional approval of AMONDYS 45, expected around April 2027 (standard review timeline from the June 30, 2026 acceptance). Approval would remove the overhang from the failed ESSENCE confirmatory trial and solidify the PMO franchise's revenue stream. Denial could threaten the drug's continued marketing and would be a significant negative for SRPT shares.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$17.82
T+0 close · Nov 5, 2026 · via day close
Latest settled
−9.82%
T+5 · $16.07 · next T+20 in 20d
Vs SPY
−12.42%
α at T+5
Latest observation
−14.46%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $17.82entry
  2. T+1 · 8d ago −3.25%α −5.62% · $17.24
  3. T+5 · 4d ago −9.82%α −12.42% · $16.07
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The company raised the low end of full-year net product revenue guidance by $50M to $1.25B-$1.3B and lowered the high end of expense guidance by $25M to $800M-$825M, driven by strong PMO franchise performance and operating discipline. Upcoming multiple ascending dose data for SRP-1003 (DM1) and SRP-1001 (FSHD) by year-end are key pipeline catalysts.

Key Financial Metrics

Revenue
$381.4M
est $350.1M · +8.9% · -5.0% YoY
Guidance
$1.25B-$1.3B
raised

Key Facts

  • Q3 2026 total revenue $381.4M, down 5% YoY from $399.4M
  • Net product revenue $323.8M: PMO $240.3M, ELEVIDYS $83.5M
  • Full-year 2026 net product revenue guidance raised to $1.25B-$1.3B (low end +$50M)
  • Full-year combined non-GAAP R&D and SG&A expense guidance narrowed to $800M-$825M (high end -$25M)
  • Cash, cash equivalents, restricted cash and investments $998.7M at Sep 30, 2026
  • MAD data for SRP-1003 (DM1) and SRP-1001 (FSHD) expected Q4 2026

Financial Impact

Revenue declined $18M YoY; GAAP operating loss improved $94.4M to $9.0M loss; guidance raised by $50M at low end

revenuenet incomeoperating incomeguidance

Risk Factors

  • ELEVIDYS revenue continues to decline due to label restriction to ambulatory patients
  • Take-or-pay charge of $62M related to Catalent manufacturing obligations
  • Upcoming DM1/FSHD data may not support advancement to Phase 3
  • Litigation settlement charge of $39M recorded in Q2 2026

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
39% bullish (31 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-449822
Document: srpt-20261105.htm0001193125-26-449822
Document: 0001193125-26-449822-index-headers.html0001193125-26-449822
Document: 0001193125-26-449822-index.html0001193125-26-449822
Document: 0001193125-26-449822.txt0001193125-26-449822
8-K Data (Synthetic)0001193125-26-449822

US Market Status

Market Closed · Opens in 8h 50m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026